Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
Nanobiotix, a late-stage clinical biotech company specializing in physics-based cancer treatments, has priced its global follow-on offering, comprising US-traded ADS and European ordinary shares, successfully raising approximately €85 million ($98.6 million). The offering was priced at a discount to recent trading prices and is oversubscribed, indi…